Product Images Xifaxan

The text is describing a study design presented in Figure 3. The study involves four treatment phases with maintenance and follow-up phases. The design includes screening and daily/weekly symptom diary maintenance for the participants. There is a mention of non-responders being withdrawn and a follow-up phase with EOS. The text does not provide further details on the type of study or the subject area.*

This appears to be a graph showing the proportion of patients without breakthrough HE over time. The hazard ratio, 95% confidence interval, and log-rank p-value are also displayed. The drug XIFAXAN may be related to these results. The x-axis represents days post-randomization and the y-axis appears to show the proportion of patients without breakthrough HE.*

This is a statistical representation of the proportion of patients without HE (hepatic encephalopathy)-related hospitalizations, comparing the effectiveness of a placebo with an experimental treatment. The hazard ratio is 0.500 (a lower number indicates better efficacy), with a 95% confidence interval of 0.287 to 0.873. The log-rank p-value is 0.0120. There are numbers listed for "2 ES 7 12 140 168" but no explanation is given for what they represent. The data appears to be tracked over a period of 8 days post-randomization.*

Xifaxan is a brand name for the drug Rifaximin which is available as 200mg tablets. The manufacturer of the drug is Salix and the lot number is MDWP with an expiration date of 07/14. The PDM number for the drug is 4980 and it is available only on prescription. The last line seems to be unreadable characters.*